Stacie Calad-Thomson

last updated 1/16/2018

Stacie Calad-Thomson

Operations, Planning and Strategy Business Manager, Platform Technology and Science (PTS), Research and Development at GlaxoSmithKline plc

5 Crescent Drive, Philadelphia, Pennsylvania, United States
HQ Phone:
(215) 751-4611

General Information


Operations, Planning and Strategy Director, Platform Technology and Science (PTS), Research and Development - GSK Corporation

Chief Operating Officer - Accelerating Therapeutics for Opportunities



PhD - chemistry , 

Recent News  

Accelerating Cancer Therapies and Exploiting Longitudinal Patient Data: Partnering to Achieve PM Session Chair: Keith R. Yamamoto, UCSF - PMWC Precision Medicine World Conference

Stacie Calad-Thomson
Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy's Lawrence Livermore National Laboratory, GSK, the National Cancer Institute's Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.

Read More

Browse ZoomInfo’s Directories